Redx pharma (REDX.LON) owns RXC005 global IP rights, with key composition-of-matter patents expected to extend up until 2035Full report is available via Capital Network website
- Overall Genedrive PLC (LON: GDR) reported a business and financial update for the six months to December 2017 in line with expectations
- Launch preparation of Genedrive® HCV test with partner Sysmex on track, expect sales to start coming through in CY2018
- £1.3mln income from the ongoing collaboration with the US DoD, in line with expectations
- Discussions for the disposal of the Services business are in progress
- With £4.6mln of cash at end-2017, and given the company's expected cash burn, a capital raise in the next 12 months can't be ruled out
- Full financial results for the six months to December 2017 to be published on March 20th
Avacta (AVCT.LON), a UK-based biotechnology company, has developed an innovative proteinscaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets.
genedrive (GDR.LON), an emerging UK medtech company, focuses on the development and commercialization of an innovative, point-of-care diagnostic system, also called Genedrive® (in this report, "genedrive" (GDR.LON) refers to the company, whereas "Genedrive®" indicates the product). genedrive (GDR.LON) is poised to become the first company to launch a decentralized Hepatitis C diagnostic, entering a large market at a time when new curative therapies for the disease are transforming opportunities for testing and treatment. A Genedrive® TB diagnostic has already been launched and the platform has a wide range of alternative applications.
No investment advice
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.